ChronoScale Corporation Common Stock (CHRN) Projected to Post Quarterly Earnings on Monday

ChronoScale Corporation Common Stock (NASDAQ:CHRN) will likely be releasing its Q2 2026 resultson Monday, July 27th. Analysts expect ChronoScale Corporation Common Stock to post earnings of ($0.06) per share and revenue of $2.5130 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($3.89) EPS for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The business had revenue of $18.09 million during the quarter. On average, analysts expect ChronoScale Corporation Common Stock to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

ChronoScale Corporation Common Stock Trading Down 4.7%

Shares of ChronoScale Corporation Common Stock stock opened at $21.50 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.55 and a quick ratio of 1.03. The firm has a fifty day moving average price of $20.23 and a 200 day moving average price of $13.90. ChronoScale Corporation Common Stock has a 1 year low of $2.91 and a 1 year high of $30.00. The stock has a market cap of $76.54 million, a PE ratio of -4.00 and a beta of 0.99.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a research report on Friday, March 27th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $6.00.

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

Large investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in ChronoScale Corporation Common Stock in the third quarter valued at approximately $57,000. Shay Capital LLC acquired a new position in shares of ChronoScale Corporation Common Stock during the 3rd quarter worth approximately $67,000. Citadel Advisors LLC purchased a new position in shares of ChronoScale Corporation Common Stock during the 3rd quarter valued at approximately $198,000. Finally, Geode Capital Management LLC lifted its position in shares of ChronoScale Corporation Common Stock by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares in the last quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.